The abstract is read at the publisher; the summary is JClub's.
Higher baseline plasma phosphorylated tau 217 (p-tau217) in 2684 cognitively unimpaired older adults is linked to increased progression risk, with a 1-SD hazard ratio of 1.38.
- Why it matters: Absolute, time-specific risk estimates for clinical progression are needed to translate blood p-tau217 into prognostic tools and to guide trial design.
- What they did: Using harmonized longitudinal data from 6 North America, Japan, and Australia cohorts, the study modeled time to cognitive impairment and change in latent PACC from baseline p-tau217.
- The result: High (1.1–2.4 SD) and very high (>2.5 SD) p-tau217 corresponded to 5-year absolute risks of 24% and 38%, respectively, and very high levels showed faster PACC decline (-0.07 vs 0.03 units/y).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.